Redeye comments briefly on Sleep Cycle's decision to appoint CTPO Mikael Kågeback as acting CEO in place of Erik Jivmark — a change that, gi...
Redeye returns with updated estimates and valuation following Sleep Cycle's Q2 2026 report, presentation and webcast Q&A.
Redeye's initial take on Sleep Cycle's Q2 2026 report is that the underlying quarter was broadly in line with our expectations, even though ...
Redeye previews Sleep Cycle ahead of its Q2 2026 report on 26 August.
Redeye briefly comments on Altor's decision to complete its offer for Sleep Cycle, despite not reaching the 90% acceptance level that was on...
Redeye briefly comments on Snark BidCo (Altor) extending its acceptance period for Sleep Cycle until July 2, 2026, while declaring its SEK 2...
Today, the independent Board of Directors of Sleep Cycle officially announced its unanimous recommendation that shareholders should not acce...
Snark BidCo (controlled by Altor) has launched a cash offer of SEK 24.
Sleep Cycle’s Q1 2026 results confirms the transition toward a multi-product platform.
Redeye’s initial take on Sleeps Cycles' Q1 report confirms the company remains on track with its 2026 investment trajectory.
Redeye shares its view on Sleep Cycle ahead of the Q1 report, as the company’s evolution into a diversified sleep health platform gains mome...
Redeye has updated its estimates and valuation for Sleep Cycle following the Q4 2025 report.
Sleep Cycle’s Q4 report was in line with our top-line expectations but revealed a steeper-than-anticipated decline in the subscriber base.
Redeye shares its view on Sleep Cycle ahead of the Q4 report, due on February 4.
Redeye has updated its estimates and valuation for Sleep Cycle following the Q3 2025 report, which showed stable profitability and further p...
Redeye comments on Sleep Cycle’s Q3 report, which was in line with expectations.
Redeye shares its view on Sleep Cycle ahead of the Q3 report due on 24 October.
Redeye has updated its estimates and valuation for Sleep Cycle following the Q2 2025 report, which was characterised by softer subscription ...
Redeye comments on Sleep Cycle’s Q2 report, which was broadly in line with expectations.
Redeye has updated its estimates and valuation for Sleep Cycle following the Q1 2025 report, which was in line with our sales and EBIT expec...
Sleep Cycle delivered a Q1 report that was broadly in line with our expectations on both sales and EBIT, despite continued subscriber headwi...
Redeye provides a preview ahead of Sleep Cycles’ Q1 2025 results.
Redeye maintains its fair value range for Sleep Cycle following the Q4 2024 report, which met our sales expectations, while EBIT exceeded ou...
Redeye provides initial comments on Sleep Cycle’s Q4 report, in which sales were in line with expectations, but EBIT came in above forecasts...
Redeye maintains its fair value range for Sleep Cycle following the Q3 2024 quarterly report, which matched our expectations on sales, while...
Redeye comments on Sleep Cycle's Q3 2024 report, which showed a growth rate of 8.
Redeye comments on the recent announcement of Sleep Cycle's partnership with MyFitnessPal, the leading global food and nutrition tracking ap...
Redeye updates its estimates on Sleep Cycle following its Q2 2024 quarterly report, which matched our expectations on sales, while the adjus...
Redeye comments on Sleep Cycle's Q2 2024 report, which came in slightly better on sales and EBIT than our estimates.
Redeye updates its estimates on Sleep Cycle following its Q1 2024 report and strategy update.
Redeye comments on Sleep Cycle's Q1 2024 report, which showed a growth rate of 13% y/y (11% currency-adjusted and an adjusted EBIT margin of...
Redeye comments on Sleep Cycle’s Capital Markets Day (CMD), including the revised financial targets.
Redeye updates its estimates after Sleep Cycle’s Q4 2023 report, which came in slightly lower on sales and EBIT.
Redeye comments on Sleep Cycle's Q4 2023 report, which continued to show a q/q growth rate in the subcriber base.
Redeye comments on Sleep Cycle’s announcement this morning regarding its strategic move to consolidate its workforce at the headquarters in ...
Redeye updates its estimates after Sleep Cycle’s Q3 2023 report, which was in line with our sales estimates but better on the profitability ...
Redeye comments on Sleep Cycle's Q3 2023 report, which was in line with our sales estimates but stronger on the margin side.
Today, Sleep Cycle announced that Carl Johan Hederoth is stepping down as the company's CEO, and that the board has decided to appoint Erik ...
Redeye is encouraged to see a stabilisation in Sleep Cycle’s total number of subscribers, thanks to successful new feature releases, improve...
Redeye comments on Sleep Cycle's Q2 2023 report, which was in line with our estimates.
Yesterday, on May 15, Sleep Cycle announced that it intends to launch cost-efficiency measures to “increase efficiency and adjust the operat...
Redeye updates its estimates on Sleep Cycle following the Q1 2023 report.
Redeye comments on Sleep Cycle's Q1 2023 report, which was relatively stable given the overall macro environment.
Redeye comments on the launch of Sleep Cycle Kids, an app providing parents with tools to optimize their childrens' sleep, among other thing...
Sleep Cycle published its preliminary Q4 2022 numbers on January 16, in light of the back-then ongoing cash offer from Velvet Cichlid AB.
Redeye comments on today’s news that Velvet Cichlid does not complete the offer of Sleep Cycle, which was conditional.
Redeye updates its estimates following Sleep Cycle's preliminary Q4 2022 numbers.
Redeye comments on Sleep Cycle's preliminary Q4 2022 numbers.
Sleep Cycle’s share has traded above the cash offer of SEK42.
Redeye comments on Velvet Cichlid's offer to buy Sleep Cycle in a cash deal.
Redeye gives a short comment on the Huawei launch in China, adding over 100 million new users to its reach.
Redeye comments on Sleep Cycle's Q3 report, which showed higher profitability than expected, while the subscriber intake was lower than anti...
Redeye updates its estimates following Sleep Cycle’s Q2’22 report.
Redeye comments on Sleep Cycle's Q2 report, which was more or less in line with our estimates.
Redeye updates its estimates for 2022, following reviews of the quarterly report, the company’s product roadmap, platform initiatives, and p...
Redeye has a positive take on Sleep Cycle's robust underlying growth.
Redeye comments on Sleep Cycle’s Q4 report, which was more or less in line with our estimates.
